Table 4.
Comparison of the clinical parameters between the patients with high and low monocyte ratio
| Variable | IPF with high monocyte ratio | IPF with low monocyte ratio | Non-IPF with high monocyte ratio | Non-IPF with low monocyte ratio | P values |
|---|---|---|---|---|---|
| Total number, n (%) | 26 (14) | 30 (17) | 62 (35) | 61 (34) | |
| Age, y | 74 ± 6 | 72 ± 8 | 72 ± 10 | 71 ± 10 | 0.365 |
| Male sex, n (%) | 24 (92) | 25 (83) | 38 (61) | 35 (57) | 0.002 |
| Blood biomarkers | |||||
| LDH, IU/L | 221.5 ± 63.1 | 203.1 ± 46.8 | 234.6 ± 97.4 | 208.8 ± 57.4 | 0.248 |
| SP-D, ng/mL | 147.9 ± 127.3 | 186.6 ± 150.8 | 180.0 ± 231.9 | 240.0 ± 310.1 | 0.503 |
| KL-6, U/mL | 689.5 ± 523.9 | 761.0 ± 344.6 | 918.5 ± 1185.4 | 877.2 ± 1384.8 | 0.130 |
| Monocyte ratio, % | 10.2 ± 1.2 | 6.6 ± 1.3 | 10.8 ± 2.8 | 6.7 ± 1.5 | < 0.001 |
| Monocyte count, /μL | 721.6 ± 283.4 | 545.1 ± 186.4 | 646.8 ± 206.5 | 451.0 ± 165.1 | < 0.001 |
| HRCT scores | |||||
| Honeycomb score, points | 0.9 ± 1.7 | 2.5 ± 3.2 | 0.2 ± 0.6 | 0.3 ± 1.0 | < 0.001 |
| GGO score, points | 4.3 ± 2.6 | 5.9 ± 2.2 | 4.8 ± 2.5 | 4.2 ± 3.5 | 0.001 |
| ILD-GAP score | 4.2 ± 0.8 | 3.8 ± 0.9 | 0.5 ± 1.0 | 0.6 ± 1.2 | < 0.001 |
| ILD-GAPM score | 5.2 ± 0.8 | 3.8 ± 0.9 | 1.5 ± 1.0 | 0.6 ± 1.2 | < 0.001 |
| Pulmonary function tests | |||||
| %FVC, %predicted | 93.8 ± 20.7 | 93.2 ± 17.1 | 97.5 ± 18.0 | 91.6 ± 19.6 | 0.277 |
| %DLco, %predicted | 80.3 ± 32.4 | 82.0 ± 23.8 | 98.8 ± 33.3 | 97.7 ± 27.0 | 0.007 |
Serum SP-D could be measured in 122 patients (68%)
Abbreviations: GAP gender/age/physiology, GAPM gender/age/physiology/blood monocyte ratio, GGO ground-glass opacity, HRCT high-resolution computed tomography, ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von den Lungen-6, LDH lactate dehydrogenase, %DLco percentage predicted diffusion capacity of lung for carbon monoxide, %FVC percentage predicted forced vital capacity, SP-D surfactant protein-D